Company intelligence / Profile preview

TiCARos Therapeutics

Ownership: Private
Development stage: Other

Overview

TiCARos has advanced its lead program TC011 into Phase I trials targeting lymphoma with promising preclinical data showing full tumor regression at low doses. The company’s proprietary platforms aim to overcome current limitations of conventional CAR-T therapies—especially in solid tumors—by improving efficacy and safety through novel engineering approaches. Additional programs are advancing through preclinical development targeting both hematologic malignancies and solid tumors.

Therapeutic areas: Oncology
Modalities: Autologous CAR-T cell therapy (Chimeric Antigen Receptor T cells)Proprietary next-generation CAR-T platforms (CLIP-CAR, Converter CAR, Switchable CAR)
Industry: Biotech

Drug pipeline

2 assets

TC091

Preclinical

1 more asset in the full pipeline.

Partnerships

Cartherics Pty Ltd. – collaborative research agreement focused on combining proprietary CLIP-CAR constructs with Cartherics’ NK cell platform for cancer immunotherapy applications.Selected by JLabs Korea/J&J support program in late–2024.KDDF Challenge awardee for solid cancer-targeting ‘CAR-T’ project in late–2024.

Beyond the preview

Go deeper on TiCARos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TiCARos Therapeutics.